Adavosertib: all 50 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingNCT02813135Phase 1/2
• A Study of Adavosertib as Treatment for Uterine Serous CarcinomaCompletedNCT04590248Phase 2Results posted
• Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction CancersActive, not recruitingNCT04460937Phase 1Results posted
• Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)Active, not recruitingNCT04439227Phase 2Results posted
• Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR StudyActive, not recruitingNCT04197713Phase 1Results posted
• Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine CancersTerminatedNCT03345784Phase 1Results posted
• To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.Active, not recruitingNCT03330847Phase 2Results posted
• AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 AmplificationCompletedNCT03253679Phase 2Results posted
• CISPLATIN + AZD-1775 In Breast CancerCompletedNCT03012477Phase 2Results posted
• A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung CancerCompletedNCT02937818Phase 2Results posted
• OLAParib COmbinationsTerminatedNCT02576444Phase 2Results posted
• AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung CancerCompletedNCT02513563Phase 2Results posted
• Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid TumoursCompletedNCT02341456Phase 1Results posted
• Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck CancerTerminatedNCT02196168Phase 2Results posted
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by SurgeryCompletedNCT02194829Phase 1/2Results posted
• Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT02101775Phase 2Results posted
• Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid TumorsCompletedNCT02095132Phase 1/2Results posted
• Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung CancerTerminatedNCT02087241Phase 2Results posted
• A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung CancerTerminatedNCT02087176Phase 2Results posted
• Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine GliomasCompletedNCT01922076Phase 1Results posted
• MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene VariationsCompletedNCT01827384Phase 2Results posted
• AZD1775 for Advanced Solid TumorsCompletedNCT01748825Phase 1Results posted
• A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)CompletedNCT01357161Phase 2Results posted
• A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)TerminatedNCT01076400Phase 1/2Results posted
• A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005TerminatedNCT01047007Phase 1Results posted
• Adavosertib and Gemcitabine in Advanced PancreaticWithdrawnNCT05212025Phase 2
• Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]AdavosertibTerminatedNCT05008913Phase 1
• A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid TumoursTerminatedNCT04949425Phase 1
• Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid TumoursCompletedNCT04462952Phase 1
• AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine CarcinosarcomaActive, not recruitingNCT03668340Phase 2
• Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT03579316Phase 2
• Prostate Cancer Biomarker Enrichment and Treatment SelectionActive, not recruitingNCT03385655Phase 2
• Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2Active, not recruitingNCT03284385Phase 2
• Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal CancerCompletedNCT02906059Phase 1
• Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT02791919Phase 1
• Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 MutationTerminatedNCT02688907Phase 2
• Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT02659241Early Phase 1
• Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid TumoursCompletedNCT02617277Phase 1
• Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.CompletedNCT02610075Phase 1
• Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer PatientsCompletedNCT02593019Phase 2
• Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCCCompletedNCT02585973Phase 1
• Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive, not recruitingNCT02546661Phase 1
• AZD1775 Combined With Olaparib in Patients With Refractory Solid TumorsCompletedNCT02511795Phase 1
• WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and NeckCompletedNCT02508246Phase 1
• Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid TumoursCompletedNCT02482311Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line ChemotherapyCompletedNCT02448329Phase 2
• Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid LeukemiaTerminatedNCT02381548Phase 1
• A Phase 0 Study of AZD1775 in Recurrent GBM PatientsCompletedNCT02207010Early Phase 1
• Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian CancerCompletedNCT01164995Phase 2

← Adavosertib overview